Inhalation CDMO Global Market Report 2024

The inhalation CDMO market size has grown strongly in recent years. It will grow from $1.94 billion in 2023 to $2.08 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to the rising prevalence of respiratory disorders, growing demand for personalized medicine, increasing outsourcing by pharmaceutical companies, and the growth of the biopharmaceutical industry.

The inhalation CDMO market size is expected to see strong growth in the next few years. It will grow to $2.7 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The forecasted growth for the upcoming period can be attributed to several factors, including a focus on precision medicine and targeted therapies, the rapid expansion of biopharmaceutical inhalation therapies, an emphasis on patient-centric solutions, the expansion of the global market, and emerging opportunities in new markets. Regulatory support for the development of inhalation drugs is also a contributing factor. Major trends expected during this period include an increasing demand for digital health solutions, the development of biologic inhalation therapies, a focus on sustainable inhaler technologies, the integration of artificial intelligence (AI) and machine learning, as well as an increase in collaborations and partnerships.

The growing prevalence of respiratory disorders is expected to drive the growth of the inhalation CDMO market. Respiratory disorders encompass a range of medical conditions affecting the respiratory system, including the organs and structures involved in breathing. Inhalation CDMOs play a crucial role in developing and manufacturing products for these disorders by providing expertise in formulating and delivering drugs to the lungs. They offer specialized infrastructure, resources, and knowledge to pharmaceutical companies looking to develop innovative inhalation therapies. For example, reports from the Australian Institute of Health and Welfare indicate an increase in respiratory disease-related deaths in Australia from 43,031 in 2020 to 46,551 in 2021. Additionally, data published by The Lancet shows a rise in new cases of RSV from 9,972 in 2020 to 11,255 in 2021, highlighting the increasing burden of respiratory disorders.

Major companies in the inhalation CDMO industry are increasingly adopting a strategic partnership approach to offer specialized drug development and delivery services. These partnerships are long-term, mutually beneficial arrangements between companies working together to achieve shared goals. For example, in May 2023, Hovione, a Portugal-based Contract Development and Manufacturing Organization, collaborated with H&T Presspart, a UK-based manufacturer of high-precision metal and plastic components for the pharmaceutical industry. Their partnership aims to develop Presspart's Sunrise Capsule-based Dry Powder Inhaler platform, focusing on creating new technologies for delivering higher doses of drugs and improving the efficiency of drug delivery to the lungs.

In June 2022, Kindeva Drug Delivery L.P., a US-based drug delivery and manufacturing company, acquired iPharma Labs, Inc., for an undisclosed sum. This strategic acquisition aimed to bolster Kindeva's presence in the expanding market for inhaled drug delivery technologies. iPharma Labs Inc., based in the US, specializes in providing contract development and manufacturing services for inhaled medicines.

Major companies operating in the inhalation cdmo market report are Pfizer Inc., Merck KGaA, Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., AptarGroup Inc., Samsung Biologics Co. Ltd., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, Cambrex Corporation, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Formosa Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Dipharma Francis Srl, Copley Scientific.

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2023. The regions covered in the inhalation cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhalation cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An inhalation contract development and manufacturing organization (CDMO) is a specialized entity that offers comprehensive services to pharmaceutical and biotechnology firms for the development and production of inhalable drugs. These services are tailored to meet the specific requirements of inhalation products and may include formulation development, analytical testing, process optimization, scale-up, and commercial manufacturing.

The primary products of inhalation CDMOs include dry powder inhalers (DPIs), metered dose inhalers (MDIs), nebulizers, and soft mist inhalers. DPIs are devices used to deliver medication to the lungs in the form of a dry powder and are utilized for various diseases such as asthma, COPD, pulmonary arterial hypertension, acute respiratory distress syndrome, and pulmonary fibrosis. These products are categorized by technology, including manual inhalers and digital inhalers, and are used by a variety of pharmaceutical companies, including large, small, and medium-sized pharmaceutical companies, as well as generic pharmaceutical companies.

The inhalation CDMO market research report is one of a series of new reports that provides inhalation CDMO market statistics, including inhalation CDMO industry global market size, regional shares, competitors with an inhalation CDMO market share, detailed inhalation CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the inhalation CDMO industry. This inhalation CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhalation contract development and manufacturing organization (CDMO) market includes revenues earned by providing services such as formulation development, analytical testing, device compatibility testing, process development and optimization, scale-up, and manufacturing. The market value includes the value of related goods sold by the service provider or included within the service offering. The inhalation contract development and manufacturing organization (CDMO) market also includes sales of metered-dose inhalers, dry powder inhalers, and inhalation suspension products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.